Trials
12 active
15 in total · 14 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy”In the company’s words, NCT06257693 on ClinicalTrials.gov
- Tested for
- Prostate Adenocarcinoma
- Main trialPhase 1
- “The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.”In the company’s words, NCT06257693 on ClinicalTrials.gov
- Other names
- enzalutamide
Other drugs for Prostate Adenocarcinoma
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- 30 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Dec 2028 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | |
| Phase 3Authorised | not given | Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial | |
| Phase 3Authorised | not given | Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial. | |
| Phase 2Authorised | not given | Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST) | |
| Phase 3Authorised | not given | Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial | |
| Phase 3Authorised | not given | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) | |
| Phase 3Authorised | not given | ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | |
| Phase 2Ended | not given | “A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer” | |
| Phase 2Authorised | not given | A multicenter, open label, randomized phase II trial to evaluate the efficacy of Talazoparib plus Enzalutamide as first line treatment for patients with Metastatic castration resistant Prostate Cancer after progression to an Androgen Receptor Pathway Inhibitor | |
| Phase 4Authorised | not given | Translational research study to discover molecular changes in patients with localized prostate cancer undergoing robotic-assisted radical prostatectomy and treated for 4 weeks with Enzalutamide compared to those not treated with Enzalutamide | |
| Phase 3Ended | not given | Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD | |
| Phase 3Authorised | not given | Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET | |
| Phase 4Ended | not given | Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer | |
| Phase 4Authorised | not given | RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC) | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026